Login to Your Account

Special ASCO 2013 Edition

T-VEC Not Top Banana, but Still in the Pudding

By Marie Powers
Staff Writer

Monday, June 3, 2013
Amgen Inc. didn't exactly take the blue ribbon for data on oncolytic immunotherapy talimogene laherparepvec, better known as T-VEC, at ASCO 2013. However, a first pass at key overall survival (OS) findings suggested the compound may still be in the mix for melanoma, though perhaps with a lower anticipated market opportunity than currently marketed Yervoy (ipilimumab, Bristol-Myers Squibb Co.) and highly anticipated PD-1 therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription